The Bull Rankings scorecard — our quality-growth score is 69.9 / 100, built from three pillars scored 0–100: Quality 61, Growth 97, Value 58 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 9% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
The market just priced a 67x multiple on earnings for a company that grew revenue 34.3% in the year to the quarter ended 2026-06-30. That’s not a bargain, but it’s not a lottery ticket either. Our model gives BeOne Medicines AG a Quality-growth score of 69.9, with the strongest pillar being Growth at 97 and the weakest Value at 58. The growth engine is real: BRUKINSA, TEVIMBRA, and the rest of the oncology portfolio are pulling patients and payers into a widening franchise. The problem isn’t the top line; it’s the price tag. The model’s reverse DCF says today’s $375.80 implies roughly 9% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten). That’s modest when the company’s revenue is still expanding at 34.3% and the PEG sits at 1.07. Either the Street is underestimating how long growth can stay this high, or it expects that growth to fade fast. The bull case leans on the 97 score for Growth; the bear case fixes on the 58 for Value and the diluting shareholders signal.
What the business actually is
BeOne Medicines sells oncology drugs. BRUKINSA, a small-molecule BTK inhibitor, treats blood cancers. TEVIMBRA, an anti-PD-1 antibody, fights solid tumors and blood cancers. SYLVANT targets multicentric Castleman disease. BAITUOWEI is aimed at breast cancer in premenopausal and perimenopausal women. PARTRUVIX covers various solid tumors. The commercial stage products already generate cash, while the clinical pipeline keeps the growth runway in view. The revenue engine is built on repeat prescriptions for chronic therapies and expanding label expansions across geographies.
Why it can (or can't) keep compounding
The durability story starts with returns. ROE sits at 12.7% in the quarter ended 2026-06-30, decent for a biotech but not eye-popping. The profit margin is healthier at 10.7%, showing pricing power in a crowded field. The moat isn’t a fortress; it’s a head start in multiple tumor types and the clinical data that keeps regulators and payers approving new indications. Competitors can copy molecules, but duplicating a decade of real-world evidence and payer relationships takes years. Our model flags “diluting shareholders” as a caution, which means the company is likely tapping equity to fund the next wave of trials and launches. That dilution chips away at per-share gains even if the pie grows. Still, the growth pillar at 97 suggests the pipeline has so far outrun the dilution.
The valuation question
The market cap is $42.5 billion and the share price $375.80, a P/E of 67. The PEG of 1.07 says that multiple is roughly in line with expected earnings growth. Our model’s reverse DCF goes further: it says today’s price embeds roughly 9% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten). That’s a bet on BRUKINSA’s next label expansion, TEVIMBRA’s penetration in China, and PARTRUVIX’s eventual approval. Revenue grew 34.3% in the year to the quarter ended 2026-06-30, but free cash flow of $1.3 billion is already a rounding error against the market cap. The 67 P/E only works if earnings keep compounding. Anything less—slower label uptake, payer pushback, or clinical setbacks—means the multiple has to compress. Optimism is priced into the P/E, if not into the cash-flow math.
The bear case
The weakest pillar is Value at 58, and the strongest skeptic’s argument is simple: at 67 times earnings, the stock already assumes a lot. The reverse DCF’s 9% implied free-cash-flow growth sits well below the 34.3% revenue growth, so the price assumes growth cools sharply. The model’s “diluting shareholders” signal confirms the suspicion that the company is funding growth with equity, turning future earnings into a smaller slice of a larger pie. If the clinical pipeline stalls or payer resistance stiffens, the multiple will reprice lower.
What would change our mind
Three metrics would flip the thesis. First, if the PEG ratio drops below 0.9, the Value pillar would firm up and the discount to implied growth would shrink. Second, if the company stops diluting shareholders—evidenced by flat or falling share count over two consecutive quarters—the dilution risk would fade. Third, if profit margins cross 15%, the durability case would strengthen even if revenue growth cools. Until then, the Growth pillar carries the story, and the price is betting on 9% free-cash-flow growth next year, slowing to 3% a year by year ten.